ArticleBlood cancer journal2011

Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production.

F L Khanim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.